相似文献
1
Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes.
Int J Environ Res Public Health. 2014 Feb 21;11(2):2328-45. doi: 10.3390/ijerph110202328.
2
Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol.
Syst Rev. 2018 Nov 15;7(1):192. doi: 10.1186/s13643-018-0847-x.
3
Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
Complement Ther Med. 2020 Aug;52:102524. doi: 10.1016/j.ctim.2020.102524. Epub 2020 Jul 22.
4
Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis.
J Ethnopharmacol. 2019 Mar 1;231:311-324. doi: 10.1016/j.jep.2018.10.033. Epub 2018 Oct 30.
5
Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
Phytomedicine. 2009 May;16(5):401-5. doi: 10.1016/j.phymed.2009.01.001. Epub 2009 Apr 10.
6
Bitter melon (Momordica charantia): a review of efficacy and safety.
Am J Health Syst Pharm. 2003 Feb 15;60(4):356-9. doi: 10.1093/ajhp/60.4.356.
7
Momordica charantia for type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2010 Feb 17(2):CD007845. doi: 10.1002/14651858.CD007845.pub2.
8
Extracts of Momordica charantia suppress postprandial hyperglycemia in rats.
J Nutr Sci Vitaminol (Tokyo). 2007 Dec;53(6):482-8. doi: 10.3177/jnsv.53.482.
9
The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial.
Complement Ther Clin Pract. 2018 Aug;32:181-186. doi: 10.1016/j.ctcp.2018.06.012. Epub 2018 Jun 28.
10
[Bitter melon to control high blood sugar].
Praxis (Bern 1994). 2004 Dec 8;93(50):2118.
引用本文的文献
1
Nutraceuticals and Supplements in Management of Prediabetes and Diabetes.
Nutrients. 2024 Dec 24;17(1):14. doi: 10.3390/nu17010014.
2
Effects of L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials.
Heliyon. 2024 May 11;10(10):e31126. doi: 10.1016/j.heliyon.2024.e31126. eCollection 2024 May 30.
3
Evaluation of acute and sub-chronic toxicity of bitter melon seed extract in Wistar rats.
Toxicol Rep. 2022 Apr 29;9:1024-1034. doi: 10.1016/j.toxrep.2022.04.024. eCollection 2022.
4
L.-Diabetes-Related Bioactivities, Quality Control, and Safety Considerations.
Front Pharmacol. 2022 May 17;13:904643. doi: 10.3389/fphar.2022.904643. eCollection 2022.
5
A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing L. fruit extracts in the type 2 diabetic subjects.
Food Nutr Res. 2022 Jan 3;66. doi: 10.29219/fnr.v66.3685. eCollection 2022.
6
L. Extract Protects Hippocampal Neuronal Cells against PAHs-Induced Neurotoxicity: Possible Active Constituents Include Stigmasterol and Vitamin E.
Nutrients. 2021 Jul 10;13(7):2368. doi: 10.3390/nu13072368.
7
Bitter Melon Extract Yields Multiple Effects on Intestinal Epithelial Cells and Likely Contributes to Anti-diabetic Functions.
Int J Med Sci. 2021 Feb 24;18(8):1848-1856. doi: 10.7150/ijms.55866. eCollection 2021.
8
Renal histopathological and biochemical changes following adjuvant intervention of and antiretroviral therapy in diabetic rats.
Iran J Basic Med Sci. 2019 Nov;22(11):1359-1367. doi: 10.22038/ijbms.2019.31848.7663.
9
Determination of cucurbitacin E in some selected herbs of ayurvedic importance through RP-HPLC.
J Ayurveda Integr Med. 2020 Jul-Sep;11(3):287-293. doi: 10.1016/j.jaim.2019.01.002. Epub 2019 Apr 10.
10
Ayurvedic polyherbal combination (PDBT) for prediabetes: A randomized double blind placebo controlled study.
J Ayurveda Integr Med. 2019 Oct-Dec;10(4):284-289. doi: 10.1016/j.jaim.2018.05.004. Epub 2019 Jan 17.
本文引用的文献
1
Prediabetes: the effects on arterial thickness and stiffness in obese youth.
J Clin Endocrinol Metab. 2014 Mar;99(3):1037-43. doi: 10.1210/jc.2013-3519. Epub 2014 Jan 1.
2
Momordica charantia (Bitter Melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues.
PLoS One. 2013 Dec 17;8(12):e84075. doi: 10.1371/journal.pone.0084075. eCollection 2013.
3
The Association between Trust in Health Care Providers and Medication Adherence among Black Women with Hypertension.
Front Public Health. 2013 Dec 5;1:66. doi: 10.3389/fpubh.2013.00066. eCollection 2013.
4
Structure modeling and antidiabetic activity of a seed protein of Momordica charantia in non-obese diabetic (NOD) mice.
Bioinformation. 2013 Aug 28;9(15):766-70. doi: 10.6026/97320630009766. eCollection 2013.
5
Traditional Indian medicines used for the management of diabetes mellitus.
J Diabetes Res. 2013;2013:712092. doi: 10.1155/2013/712092. Epub 2013 Jun 5.
6
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.
Endocr Pract. 2013 May-Jun;19(3):536-57. doi: 10.4158/EP13176.CS.
7
Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae).
Phytomedicine. 1996 Mar;2(4):349-62. doi: 10.1016/S0944-7113(96)80080-8.
8
Traditional medicinal herbs and food plants have the potential to inhibit key carbohydrate hydrolyzing enzymes in vitro and reduce postprandial blood glucose peaks in vivo.
ScientificWorldJournal. 2012;2012:285284. doi: 10.1100/2012/285284. Epub 2012 Feb 20.
9
Bitter melon seed oil-attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue.
J Nutr. 2012 Jul;142(7):1197-204. doi: 10.3945/jn.112.159939. Epub 2012 May 23.
10
Binding Energy calculation of GSK-3 protein of Human against some anti-diabetic compounds of Momordica charantia linn (Bitter melon).
Bioinformation. 2012;8(6):251-4. doi: 10.6026/97320630008251. Epub 2012 Mar 31.
Zotero 插件